South African Competition Commission on excessive pricing of breast cancer treatment drug
On 8 February 2022, the Competition Commission of South Africa filed a referral with the Competition Tribunal for prosecution of Roche on alleged excessive pricing of its breast cancer treatment drug, Trastuzumab. The Commission cited contravention of Section 8(1)(a) of the South African Competition Act. “8. Abuse of dominance prohibited (1) It is prohibited for a dominant firm to— (a) charge an excessive price to the detriment of consumers or customers; …… (2) If there is a prima facie case …